US Brand Name(s): Zydelig
Use of Idelalisib in Cancer Treatment
Experts have authorized Idelalisib for usage alone or in combination with other medications to treat:
- Recurrence of chronic lymphocytic leukaemia (CLL) (come back). However, it is given in combination with rituximab to patients who cannot be treated with rituximab alone.
- Recurrence of non-Hodgkin lymphoma (NHL) (come back). Experts prescribe it for individuals who have already had two systemic therapies. Also, they utilise it in the following NHL types:
- Non-Hodgkin lymphoma of the follicular B-cell type.
- Lymphocytic lymphoma of the small lymphocytes.
The FDA’s Accelerated Approval Program has authorised these uses. A confirmatory study (or trials) must prove that idelalisib offers a therapeutic benefit in these individuals as a condition of approval.
Detailed scientific definition – Definition from the NCI Drug Dictionary
Idelalisib Facts on MedlinePlus – A summary of key information regarding this medication in layman’s terms, which may contain the following:
Cautions about this medicine; what are its uses and how to use it; what you should tell your doctor before taking it; things you should know about it before using it; other drugs that might interact with it; and possible negative effects.
Experts frequently investigate drugs to see whether they can treat or prevent conditions other than those with authorization. This patient information leaflet only covers authorized uses of the medications. However, much of the material might also apply to authorized uses under investigation.
